- Home
- SYRE vs QQQX Comparison
SYRE vs QQQX Comparison
Compare SYRE & QQQX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- QQQX
- Stock Information
- Founded
- SYRE 2013
- QQQX 2007
- Country
- SYRE United States
- QQQX United States
- Employees
- SYRE N/A
- QQQX N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- QQQX Finance Companies
- Sector
- SYRE Health Care
- QQQX Finance
- Exchange
- SYRE Nasdaq
- QQQX Nasdaq
- Market Cap
- SYRE 1.1B
- QQQX 1.3B
- IPO Year
- SYRE 2016
- QQQX N/A
- Fundamental
- Price
- SYRE $15.86
- QQQX $27.60
- Analyst Decision
- SYRE Buy
- QQQX
- Analyst Count
- SYRE 5
- QQQX 0
- Target Price
- SYRE $55.00
- QQQX N/A
- AVG Volume (30 Days)
- SYRE 414.7K
- QQQX 127.6K
- Earning Date
- SYRE 11-06-2025
- QQQX 01-01-0001
- Dividend Yield
- SYRE N/A
- QQQX 7.03%
- EPS Growth
- SYRE N/A
- QQQX N/A
- EPS
- SYRE N/A
- QQQX N/A
- Revenue
- SYRE N/A
- QQQX N/A
- Revenue This Year
- SYRE N/A
- QQQX N/A
- Revenue Next Year
- SYRE N/A
- QQQX N/A
- P/E Ratio
- SYRE N/A
- QQQX N/A
- Revenue Growth
- SYRE N/A
- QQQX N/A
- 52 Week Low
- SYRE $10.91
- QQQX $20.27
- 52 Week High
- SYRE $40.26
- QQQX $25.99
- Technical
- Relative Strength Index (RSI)
- SYRE 42.99
- QQQX 69.41
- Support Level
- SYRE $15.80
- QQQX $27.23
- Resistance Level
- SYRE $17.58
- QQQX $27.63
- Average True Range (ATR)
- SYRE 0.74
- QQQX 0.21
- MACD
- SYRE -0.11
- QQQX 0.05
- Stochastic Oscillator
- SYRE 9.78
- QQQX 99.99
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek an attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.